Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 25 June, 2010 and appeared in  MedicationType 1 DiabetesIssue 527

Potential for Diabetes Patients to Create Their Own Insulin

Researchers have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of Type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.... 

Advertisement

The findings are important because, until now, it has been generally believed that, in humans, beta cells divide only very infrequently after the first year or so of life and that they do not readily proliferate once Type 1 diabetes is diagnosed. By studying the same unique collection of pancreas specimens that last year led the research team to conclude that some cases of Type 1 diabetes may have a viral cause, this current study presents evidence that there is a 10-fold increase in islet cell replication in patients recently diagnosed with Type 1 diabetes. A similar response had been seen previously in an animal model of Type 1 diabetes by a member of the team, Professor Adrian Bone (University of Brighton) but it was not known if accelerated β-cell replication also occurs in human patients.

The factors that trigger the replication process in patients with Type 1 diabetes are still unclear, although the study shows a correlation with the infiltration of immune cells (which suggests that an immune mediator is likely to be involved).

The results of the research offer the hope that, in future, it might be possible to encourage a newly diagnosed Type 1 diabetes patient's own beta cells to reproduce as a means of replacing those being destroyed by the disease. The development of such a therapy could mean that some patients with Type 1 diabetes would be able to produce their own insulin for a longer period, thereby reducing the need for pharmaceutical interventions.

Professor Noel Morgan, Director of the Institute of Biomedical and Clinical Sciences at the Peninsula Medical School, commented: "Our findings are significant because they challenge current thinking and offer the hope that, at some point in the future, a therapy could be developed that would allow individuals who are developing Type 1 diabetes to retain their own insulin. We are a long way from this point, but the first steps have been taken with this research."

He added: "We could not have come to our current conclusions without access to the unique collection of pancreas specimens from patients who died soon after being diagnosed with Type 1 diabetes, which was collected by our colleague Dr. Alan Foulis from the Department of Pathology at Glasgow Royal Infirmary. The specimens are allowing us to investigate the cellular processes that occur in the beta cells of people with Type 1 diabetes in a way that has not been possible before."

Published on-line at Diabetologia June 2010

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 25 June, 2010 and appeared in  MedicationType 1 DiabetesIssue 527

Past five issues: Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 | Issue 742 | Diabetes Clinical Mastery Series Issue 201 | Humulin Insulin Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
Statin Adherence Linked to New Onset Diabetes Risk
Posted July 25, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
HbA1c Increases with Age
Posted August 01, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
Regression from Prediabetes to Normal Glucose Reduces CVD Risk
Posted July 25, 2014
Connection between Type 1 Diabetes and Ulcerative Colitis?
Posted August 01, 2014
New Way to Regenerate Beta Cells in Type 1 Diabetes Patients
Posted August 08, 2014
Comparing Weekly Dulaglutide to Daily Liraglutide
Posted August 01, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you recommend SGLT-2 drugs for type 1 diabetes?
CME/CE of the Week
Category: Nutrition
CE Credits: .5



Search Articles On Diabetes In Control